OSUR

OraSure Technologies, Inc.

$3.33

-5.67%
SectorHealthcareIndustryMedical Instruments & SuppliesCountryUnited States

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products and specimen collection devices in the United States, Europe, Africa, and internationally. It offers OraQuick Rapid HIV test, OraQuick HIV self-test, OraQuick HIV self-test(international), OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, SickleSCAN test, and OraSure oral fluid collection device for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. The company also provides genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of urine samples; and HEMAcollect protein blood collection device.

Source: Yahoo Finance
AI summary

Price & performance

1M-14.6%
3M-16.8%
YTD+39.9%
1Y+42.9%
52-week range—
Beta1.13
Full chart and returns against a benchmark

Q-Score

42/ 100

Quality against peers; 50 is the peer median.

Growth35
Risk52
Performance38
Valuation55
Profitability42
Leverage66
Sentiment—
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$115M-38.1%
Net income-$68.7M
Net margin-59.8%-49.3 pts
Historical fundamentals

Revenue exposure

32%of revenue from outside the US
United States68%
Africa21%
Europe6%
Largest customer24%
Regions, segments, customers and suppliers

Valuation

OSURIndustryP/E—49.36P/S1.983.73EV/EBITDA—23.12P/B0.753.92PEG——
Dividend yield0.00%
Every valuation metric

Earnings

Nov 9next report, after the close
EPS estimate$-0.18
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate